Athira Pharma (ATHA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	49.07 mm	49.07 mm	49.07 mm	49.07 mm	49.07 mm	49.07 mm
Cash burn (monthly)	9.60 mm	3.51 mm	5.19 mm	8.41 mm	8.67 mm	8.10 mm
Cash used (since last report)	19.96 mm	7.30 mm	10.79 mm	17.49 mm	18.03 mm	16.84 mm
Cash remaining	29.11 mm	41.76 mm	38.28 mm	31.58 mm	31.04 mm	32.23 mm
Runway (months of cash)	3.0	11.9	7.4	3.8	3.6	4.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ATHA institutional ownership history Ownership history

56.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	59	60	-1.7%
Opened positions	8	10	-20.0%
Closed positions	9	16	-43.8%
Increased positions	6	14	-57.1%
Reduced positions	20	16	+25.0%

13F shares	Current	Prev Q	Change
Total value	10.06 bn	6.78 bn	+48.3%
Total shares	21.72 mm	17.13 mm	+26.8%
Total puts	800.00	68.00 k	-98.8%
Total calls	17.20 k	111.80 k	-84.6%
Total put/call ratio	0.0	0.6	-92.4%

Largest owners	Shares	Value	Change
Perceptive Advisors	5.40 mm	$3.17 bn	0.0%
BML Investment Partners	2.78 mm	$1.48 mm	NEW
BML Capital Management	2.78 mm	$1.63 bn	NEW
Vanguard	1.56 mm	$913.75 mm	-3.5%
Simplify Asset Management	1.49 mm	$875.82 mm	0.0%
Propel Bio Management	1.49 mm	$875.82 mm	0.0%
Venrock Healthcare Capital Partners II	1.00 mm	$0.00	0.0%
Tang Capital Management	600.00 k	$352.02 mm	0.0%
BlackRock	458.77 k	$269.16 mm	-14.3%
Acadian Asset Management	434.49 k	$254.00 k	-8.8%

Largest transactions	Shares	Bought/sold	Change
BML Investment Partners	2.78 mm	+2.78 mm	NEW
BML Capital Management	2.78 mm	+2.78 mm	NEW
Dimensional Fund Advisors	0.00	-321.45 k	EXIT
Qube Research & Technologies	350.01 k	+286.97 k	+455.3%
Two Sigma Investments	0.00	-258.47 k	EXIT
Renaissance Technologies	207.30 k	-245.49 k	-54.2%
RY Royal Bank of Canada	183.02 k	+174.68 k	+2094.2%
Pathstone	372.20 k	-119.93 k	-24.4%
Gsa Capital Partners	296.56 k	-100.56 k	-25.3%
Bridgeway Capital Management	0.00	-88.89 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ATHA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jan 25	Mark Worthington	Common Stock	Sell	Dispose S	No	No	0	8,510	0.00	83,735
2 Jan 25	Martin Javier San	Common Stock	Sell	Dispose S	No	No	0	10,826	0.00	35,841
2 Jan 25	Mark James Litton	Common Stock	Sell	Dispose S	No	No	0	25,107	0.00	242,591
2 Jan 25	Kevin Church	Common Stock	Sell	Dispose S	No	No	0.5619	8,510	4.78 k	130,761
2 Jan 25	Robert Renninger	Common Stock	Sell	Dispose S	No	No	0	2,881	0.00	89,724
31 Dec 24	Mark Worthington	Common Stock	Option exercise	Acquire M	No	No	0	36,667	0.00	92,245
31 Dec 24	Mark Worthington	RSU Common Stock	Option exercise	Dispose M	No	No	0	36,667	0.00	73,333
31 Dec 24	Martin Javier San	Common Stock	Option exercise	Acquire M	No	No	0	46,667	0.00	46,667
31 Dec 24	Martin Javier San	RSU Common Stock	Option exercise	Dispose M	No	No	0	46,667	0.00	93,333
31 Dec 24	Mark James Litton	Common Stock	Option exercise	Acquire M	No	No	0	108,333	0.00	267,698

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Athira Pharma FY 2024 GAAP EPS $(2.52) Beats $(2.54) Estimate

27 Feb 25

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(2.52) per share which beat the analyst consensus estimate of $(2.54) by 0.79 percent.

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND

6 Dec 24

Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting

Press releases

From Benzinga Pro

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

6 Dec 24

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow